Financial reports
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
31 Jul 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-Q
2023 Q1
Quarterly report
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
29 Jul 22
10-Q
2022 Q1
Quarterly report
29 Apr 22
10-K
2021 FY
Annual report
17 Feb 22
Current reports
8-K
Other Events
26 Mar 24
8-K
Other Events
21 Dec 23
8-K
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
23 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
2 Oct 23
8-K
Galecto Announces Plans to Explore Strategic Alternatives
26 Sep 23
8-K
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
15 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Results of Operations and Financial Condition
6 Jan 23
8-K
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
31 Oct 22
Registration and prospectus
S-8
Registration of securities for employees
8 Mar 24
S-8
Registration of securities for employees
9 Mar 23
424B5
Prospectus supplement for primary offering
9 Mar 23
424B5
Prospectus supplement for primary offering
18 Feb 22
S-8
Registration of securities for employees
17 Feb 22
S-3
Shelf registration
4 Nov 21
S-8
Registration of securities for employees
29 Mar 21
D
$64.2M in equity, sold $64.2M, 42 investors
5 Nov 20
S-8
Registration of securities for employees
4 Nov 20
424B4
Prospectus supplement with pricing info
30 Oct 20
Proxies
PRE 14A
Preliminary proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
14 Apr 21
DEF 14A
Definitive proxy
14 Apr 21
Other
EFFECT
Notice of effectiveness
15 Nov 21
CORRESP
Correspondence with SEC
10 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
EFFECT
Notice of effectiveness
29 Oct 20
CERT
Certification of approval for exchange listing
28 Oct 20
CORRESP
Correspondence with SEC
26 Oct 20
CORRESP
Correspondence with SEC
23 Oct 20
CORRESP
Correspondence with SEC
23 Oct 20
CORRESP
Correspondence with SEC
20 Oct 20
UPLOAD
Letter from SEC
19 Oct 20
Ownership
4
Hans T. Schambye
5 Jan 24
4
Garrett Winslow
5 Jan 24
4
Jonathan Freve
5 Jan 24
SC 13G
Otto Erik
3 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
144
Notice of proposed sale of securities
2 Oct 23
SC 13D/A
ORBIMED ADVISORS LLC
18 Sep 23
SC 13D/A
ORBIMED ADVISORS LLC
5 Sep 23